The progressive elevation of NT-proBNP during chemotherapy is related to asymptomatic cardiovascular events in patients with multiple myeloma

Multiple myeloma (MM) is a malignant monoclonal plasma cell disorder that accounts for 10% of all hematological malignancies.1, 2 The survival of patients with MM has improved significantly in the last decade due to a combination of immunomodulatory agents, corticosteroids, and proteasome inhibitors.3, 4 Meanwhile, multidrug therapy and long-term treatment have raised the incidence of treatment-related cardiovascular events (CVEs). CVEs are increasingly relevant to prognosis and even contribute to early mortality in patients with MM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research